BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension. Am J Nephrol. 2003;23:229-244. [PMID: 12840599 DOI: 10.1159/000072054] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Sato N, Saijo Y, Sasagawa Y, Morimoto H, Takeuchi T, Sano H, Koyama S, Takehara N, Morita K, Sumitomo K, Maruyama J, Kikuchi K, Hasebe N. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension 2013;31:1245-55. [DOI: 10.1097/hjh.0b013e32835fdf60] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Ma G, Allen TJ, Cooper ME, Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. Kidney International 2004;66:1090-8. [DOI: 10.1111/j.1523-1755.2004.00859.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
3 Navar LG, Arendshorst WJ, Pallone TL, Inscho EW, Imig JD, Bell PD. The Renal Microcirculation. Microcirculation. Elsevier; 2008. pp. 550-683. [DOI: 10.1016/b978-0-12-374530-9.00015-2] [Cited by in Crossref: 23] [Article Influence: 1.8] [Reference Citation Analysis]
4 Ohashi N, Mitamura H, Ogawa S. Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation. Drugs 2009;69:21-30. [PMID: 19192934 DOI: 10.2165/00003495-200969010-00002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
5 Verdecchia P, Reboldi GP. Hypertension and microalbuminuria: the new detrimental duo. Blood Pressure 2009;13:198-211. [DOI: 10.1080/08037050410016456] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
6 Furukawa T, Nukada T, Miura R, Ooga K, Honda M, Watanabe S, Koganesawa S, Isshiki T. Differential Blocking Action of Dihydropyridine Ca2+ Antagonists on a T-Type Ca2+ Channel (α1G) Expressed in Xenopus Oocytes. Journal of Cardiovascular Pharmacology 2005;45:241-6. [DOI: 10.1097/01.fjc.0000154374.88283.15] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
7 Sonkusare S, Fraer M, Marsh JD, Rusch NJ. Disrupting calcium channel expression to lower blood pressure: new targeting of a well-known channel. Mol Interv 2006;6:304-10. [PMID: 17200457 DOI: 10.1124/mi.6.6.3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Lin YC, Wang JC, Wu MS, Lin YF, Chen CR, Chen CY, Chen KC, Peng CC. Nifedipine Exacerbates Lipogenesis in the Kidney via KIM-1, CD36, and SREBP Upregulation: Implications from an Animal Model for Human Study. Int J Mol Sci 2020;21:E4359. [PMID: 32575412 DOI: 10.3390/ijms21124359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Fogari R, Mugellini A, Circelli M, Cremonesi G. Combination delapril/manidipine as antihypertensive therapy in high-risk patients. Clin Drug Investig 2011;31:439-53. [PMID: 21627336 DOI: 10.2165/11589000-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Kitamura K, Hayashi K, Ito S, Hoshina Y, Sakai M, Yoshino K, Endo K, Fujitani S, Suzuki T. Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic and antihypertensive medications. Hypertens Res 2021;44:508-17. [PMID: 33311577 DOI: 10.1038/s41440-020-00590-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pruijm MT, Maillard MP, Burnier M. Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc Health Risk Manag 2008;4:1159-66. [PMID: 19337529 DOI: 10.2147/vhrm.s3510] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
12 Lambertucci L, Di Serio C, Castellani S, Torrini M, Lotti E, Cristofari C, Masotti G, Marchionni N, Ungar A. Trandolapril, but not Verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension. Translational Research 2011;157:348-56. [DOI: 10.1016/j.trsl.2010.12.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Ohno S, Yokoi H, Mori K, Kasahara M, Kuwahara K, Fujikura J, Naito M, Kuwabara T, Imamaki H, Ishii A, Saleem MA, Numata T, Mori Y, Nakao K, Yanagita M, Mukoyama M. Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure. Sci Rep 2016;6:27192. [PMID: 27273361 DOI: 10.1038/srep27192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
14 Simonetti GD, Santoro L, Ferrarini A, Crosazzo-Franscini L, Fossali E, Bianchetti MG; CHILD Project. Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management. Paediatr Drugs 2007;9:413-8. [PMID: 18052411 DOI: 10.2165/00148581-200709060-00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Arima S. Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation. J Steroid Biochem Mol Biol 2006;102:170-4. [PMID: 17045798 DOI: 10.1016/j.jsbmb.2006.09.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Ozawa Y, Hayashi K, Kobori H. New Generation Calcium Channel Blockers in Hypertensive Treatment. Curr Hypertens Rev 2006;2:103-11. [PMID: 19823601 DOI: 10.2174/157340206776877370] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
17 Fujimoto S, Satoh M, Nagasu H, Horike H, Sasaki T, Kashihara N. Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats. Nephrology Dialysis Transplantation 2009;24:3651-8. [DOI: 10.1093/ndt/gfp407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
18 Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Chiurchiu C, Barlovic DP, Sghirlanzoni A, Lombardi R, Penza P, Cavaletti G, Piatti ML, Frigeni B, Filipponi M, Rubis N, Noris G, Motterlini N, Ene-iordache B, Gaspari F, Perna A, Zaletel J, Bossi A, Dodesini AR, Trevisan R, Remuzzi G; for the DEMAND Study Investigators. Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial. Hypertension 2011;58:776-83. [DOI: 10.1161/hypertensionaha.111.174474] [Cited by in Crossref: 59] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
19 Zhou X, Frohlich ED. Differential Effects of Antihypertensive Drugs on Renal and Glomerular Hemodynamics and Injury in the Chronic Nitric-Oxide-Suppressed Rat. Am J Nephrol 2005;25:138-52. [DOI: 10.1159/000085358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Sato N, Saijo Y, Sasagawa Y, Morimoto H, Takeuchi T, Sano H, Koyama S, Takehara N, Morita K, Sumitomo K, Maruyama J, Kikuchi K, Hasebe N; the CAMUI Investigators. Visit-to-visit variability and seasonal variation in blood pressure: Combination of Antihypertensive Therapy in the Elderly, Multicenter Investigation (CAMUI) Trial subanalysis. Clinical and Experimental Hypertension 2014;37:411-9. [DOI: 10.3109/10641963.2014.995802] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
21 Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs 2006;8:357-73. [PMID: 17154643 DOI: 10.2165/00148581-200608060-00004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
22 Grassi G, Robles NR, Seravalle G, Fici F. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother 2017;8:155-65. [PMID: 29472747 DOI: 10.4103/jpp.JPP_34_17] [Cited by in Crossref: 11] [Article Influence: 2.8] [Reference Citation Analysis]
23 Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012;344:d8190. [PMID: 22240117 DOI: 10.1136/bmj.d8190] [Cited by in Crossref: 131] [Cited by in F6Publishing: 91] [Article Influence: 14.6] [Reference Citation Analysis]
24 Coca A, Mazón P, Aranda P, Redón J, Divisón JA, Martínez J, Calvo C, Galcerán JM, Barrios V, Coll ARI. Role of dihydropyridinic calcium channel blockers in the management of hypertension. Expert Review of Cardiovascular Therapy 2014;11:91-105. [DOI: 10.1586/erc.12.155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
25 Roca-Cusachs A, Triposkiadis F. Antihypertensive effect of manidipine. Drugs 2005;65 Suppl 2:11-9. [PMID: 16398058 DOI: 10.2165/00003495-200565002-00003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
26 Hayashi K, Saruta T, Goto Y, Ishii M; JATOS Study Group. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res 2010;33:1211-20. [PMID: 20844543 DOI: 10.1038/hr.2010.162] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
27 Skov K, Mulvany MJ. Structure of renal afferent arterioles in the pathogenesis of hypertension. Acta Physiol Scand 2004;181:397-405. [DOI: 10.1111/j.1365-201x.2004.01311.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
28 Ott C, Schneider MP, Raff U, Ritt M, Striepe K, Alberici M, Schmieder RE. Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. Br J Clin Pharmacol. 2013;75:129-135. [PMID: 23240643 DOI: 10.1111/j.1365-2125.2012.04336.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
29 Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 2005;65 Suppl 2:1-10. [PMID: 16398057 DOI: 10.2165/00003495-200565002-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
30 McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64:1923-1940. [PMID: 15329044 DOI: 10.2165/00003495-200464170-00011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
31 Nagasawa K, Takahashi K, Matsuura N, Takatsu M, Hattori T, Watanabe S, Harada E, Niinuma K, Murohara T, Nagata K. Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertens Res 2015;38:39-47. [DOI: 10.1038/hr.2014.136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
32 Zhou X, Frohlich ED. Physiologic evidence of renoprotection by antihypertensive therapy. Curr Opin Cardiol 2005;20:290-5. [PMID: 15956825 DOI: 10.1097/01.hco.0000161226.67093.e3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Rizos CV. Manidipine: A different dihydropyridine. WJH 2011;1:3. [DOI: 10.5494/wjh.v1.i1.3] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
34 Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005;61:483-490. [PMID: 16021438 DOI: 10.1007/s00228-005-0961-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
35 Sugano N, Wakino S, Kanda T, Tatematsu S, Homma K, Yoshioka K, Hasegawa K, Hara Y, Suetsugu Y, Yoshizawa T, Hara Y, Utsunomiya Y, Tokudome G, Hosoya T, Saruta T, Hayashi K. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008;73:826-34. [PMID: 18200001 DOI: 10.1038/sj.ki.5002793] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
36 Syme HM, Elliott J. Proteinuria. Consultations in Feline Internal Medicine. Elsevier; 2006. pp. 415-22. [DOI: 10.1016/b0-72-160423-4/50048-2] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
37 Chua DC, Bakris GL. Is proteinuria a plausible target of therapy? Curr Hypertens Rep 2004;6:177-81. [PMID: 15128468 DOI: 10.1007/s11906-004-0066-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
38 Reboldi G, Gentile G, Angeli F, Verdecchia P. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Review of Cardiovascular Therapy 2014;7:1349-61. [DOI: 10.1586/erc.09.133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
39 Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag 2009;5:411-27. [PMID: 19475778 DOI: 10.2147/vhrm.s4235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
40 Martell-Claros N, de la Cruz JJ. Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study. Clin Drug Investig 2011;31:427-34. [PMID: 21528940 DOI: 10.2165/11587400-000000000-00000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
41 Arima S. Aldosterone and the kidney: Rapid regulation of renal microcirculation. Steroids 2006;71:281-5. [DOI: 10.1016/j.steroids.2005.09.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
42 Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease: . Current Opinion in Nephrology and Hypertension 2004;13:155-61. [DOI: 10.1097/00041552-200403000-00003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
43 Abe M, Okada K, Suzuki H, Yoshida Y, Soma M. T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease. BMC Nephrol 2013;14:135. [PMID: 23815742 DOI: 10.1186/1471-2369-14-135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Cavalieri L, Cremonesi G. Metabolic Effects of Manidipine. Am J Cardiovasc Drugs 2009;9:163-76. [DOI: 10.1007/bf03256573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K, Kusaka H, Matsubara M. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008;584:424-34. [PMID: 18331727 DOI: 10.1016/j.ejphar.2008.02.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
46 Bakris GL, Weir MR, Secic M, Campbell B, Weis-mcnulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney International 2004;65:1991-2002. [DOI: 10.1111/j.1523-1755.2004.00620.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 100] [Article Influence: 8.5] [Reference Citation Analysis]
47 Pallone TL, Edwards A, Mattson DL. Renal Medullary Circulation. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 97-140. [DOI: 10.1002/cphy.c100036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
48 Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol 2012;350:223-34. [PMID: 21801805 DOI: 10.1016/j.mce.2011.07.019] [Cited by in Crossref: 76] [Cited by in F6Publishing: 60] [Article Influence: 7.6] [Reference Citation Analysis]
49 Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65 Suppl 2:29-39. [PMID: 16398060 DOI: 10.2165/00003495-200565002-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
50 Lin YC, Lin JW, Wu MS, Chen KC, Peng CC, Kang YN. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. PLoS One 2017;12:e0188975. [PMID: 29240784 DOI: 10.1371/journal.pone.0188975] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
51 Aritomi S, Niinuma K, Ogawa T, Konda T, Nitta K. Effects of an N-type calcium antagonist on angiotensin II-renin feedback. Am J Nephrol 2011;33:168-75. [PMID: 21293118 DOI: 10.1159/000323969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
52 Kosaka H, Hirayama K, Yoda N, Sasaki K, Kitayama T, Kusaka H, Matsubara M. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 2010;635:49-55. [PMID: 20307534 DOI: 10.1016/j.ejphar.2010.03.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
53 Xie X, Van Deusen AL, Vitko I, Babu DA, Davies LA, Huynh N, Cheng H, Yang N, Barrett PQ, Perez-reyes E. Validation of High Throughput Screening Assays Against Three Subtypes of Ca v 3 T-Type Channels Using Molecular and Pharmacologic Approaches. ASSAY and Drug Development Technologies 2007;5:191-204. [DOI: 10.1089/adt.2006.054] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
54 Robles NR. Calcium Antagonists and Renal Failure Progression. Renal Failure 2009;30:247-55. [DOI: 10.1080/08860220701856946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
55 Robles NR, Fici F, Grassi G. Dihydropyridine calcium channel blockers and renal disease. Hypertens Res 2017;40:21-8. [DOI: 10.1038/hr.2016.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
56 Bhattacharjee N, Barma S, Konwar N, Dewanjee S, Manna P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. Eur J Pharmacol. 2016;791:8-24. [PMID: 27568833 DOI: 10.1016/j.ejphar.2016.08.022] [Cited by in Crossref: 123] [Cited by in F6Publishing: 106] [Article Influence: 24.6] [Reference Citation Analysis]
57 Omae K, Ogawa T, Nitta K. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart Vessels 2009;24:301-7. [PMID: 19626404 DOI: 10.1007/s00380-008-1125-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
58 Furukawa T, Miura R, Honda M, Kamiya N, Mori Y, Takeshita S, Isshiki T, Nukada T. Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br J Pharmacol 2004;143:1050-7. [PMID: 15545287 DOI: 10.1038/sj.bjp.0705944] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
59 Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int 2008;73:795-6. [PMID: 18340349 DOI: 10.1038/sj.ki.5002773] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
60 Ruilope LM, Kirwan BA, de Brouwer S, Danchin N, Fox KA, Wagener G, Segura J, Poole-Wilson PA, Lubsen J; ACTION investigators. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens 2007;25:1711-8. [PMID: 17620970 DOI: 10.1097/HJH.0b013e3281c49d93] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
61 Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Review of Cardiovascular Therapy 2014;5:147-59. [DOI: 10.1586/14779072.5.2.147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]